This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Night Watch: Chattem Lower on Secondary

WorldCom (WCOM) was the most actively traded issue in the Instinet late session Monday, although the company ? which saw its debt further lowered into the realm of junk earlier ? was treading water after falling 9% in regular trading.

Shares of the long-distance company were unchanged at $1.45 each after S&P lowered by two notches its long-term corporate credit rating.

A couple of wireless companies were also atop the volume list but unchanged: U.S. Unwired (UNWR) held steady at $2.99 while Triton PCS (TPC) was even with its 4 p.m. close at $5.59.

Elsewhere, Vasomedical (VASO) gave back 16 cents to $2.68 after almost doubling in the regular session on expanded FDA approval for its chest pain therapy. The company's shares rose 82% to close at $2.84 at 4 p.m. EDT on the FDA's decision, which could expand the number of patients eligible for the treatment by up to 20%.

Other stocks falling in the late session included Tuesday Morning (TUES), down 13.4% to $18.52; Chattem (CHTT), down 7.6% to $33.15 after announcing a secondary offering; and Tellium (TELM), which gave back 5 cents to $1.16 after rising 10 cents to $1.21 in the regular session.

On the upside, Dynegy (DYN) was gaining 25 cents to $8.80; ValueVision Media (VVTV) was up 50 cents to $19.20 after affirming sales goals; and Neoforma (NEOF) was gaining 23 cents to $12.23 after saying several companies had agreed to use its e-commerce product.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs